Advances and strategies in discovery of new antibacterials for combating metabolically resting bacteria

Drug Discovery Today

Volumn 18, Issue 5-6, 2013, Pages 250-255

  Bald, Dirk ^a,b   Koul, Anil ^c  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b AMSTERDAM INSTITUTE FOR MOLECULES   (Netherlands)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BEDAQUILINE; BENZIMIDAZOLE DERIVATIVE; CLOFAZIMINE; DAPTOMYCIN; IMIDAZOPYRIDINE DERIVATIVE; POLYPEPTIDE ANTIBIOTIC AGENT; PYRAZINAMIDE; THIOPHENE; UNCLASSIFIED DRUG; VANCOMYCIN; XF 73;

ANTIBIOTIC SENSITIVITY; BACTERIAL GROWTH; BACTERIAL METABOLISM; BACTERICIDAL ACTIVITY; BACTERIUM; CARBOHYDRATE METABOLISM; CHEMOTHERAPY; DOWN REGULATION; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENCY; DRUG SAFETY; DRUG SCREENING; ENVIRONMENTAL FACTOR; ESCHERICHIA COLI; HUMAN; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PROTEIN SYNTHESIS; REVIEW; STAPHYLOCOCCUS AUREUS; TREATMENT DURATION; URINARY TRACT INFECTION;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; DRUG DISCOVERY;

EID: 84874755540     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2012.09.007     Document Type: Review

References (60)

1. T. Braine Bull. World Health Organ. 89 2011 88 89
2. K. Bush Tackling antibiotic resistance Nat. Rev. Microbiol. 9 2011 894 896
3. B. Spellberg Combating antimicrobial resistance: policy recommendations to save lives Clin. Infect. Dis. 52 Suppl. 5 2011 S397 S428
4. M.S. Butler, and M.A. Cooper Antibiotics in the clinical pipeline in 2011 J. Antibiot. (Tokyo) 64 2011 413 425
5. K. Lewis Antibiotics: recover the lost art of drug discovery Nature 485 2012 439 440
6. M.A. Fischbach, and C.T. Walsh Antibiotics for emerging pathogens Science 325 2009 1089 1093
7. A. Koul The challenge of new drug discovery for tuberculosis Nature 469 2011 483 490
8. C.M. Tan Restoring methicillin-resistant Staphylococcus aureus susceptibility to β-lactam antibiotics Sci. Transl. Med. 283 2012 12769 12776
9. M.S. Butler, and M.A. Cooper Screening strategies to identify new antibiotics Curr. Drug Targets 13 2012 373 387
10. H.H. Lee, and J.J. Collins Microbial environments confound antibiotic efficacy Nat. Chem. Biol. 8 2011 6 9
11. K.R. Allison Heterogeneous bacterial persisters and engineering approaches to eliminate them Curr. Opin. Microbiol. 14 2011 593 598
12. J.G. Hurdle Targeting bacterial membrane function: an underexploited mechanism for treating persistent infections Nat. Rev. Microbiol. 9 2011 62 75
13. M.V. Ranall Resolving biofilm infections: current therapy and drug discovery strategies Curr. Drug Targets 2012 [Epub ahead of print]
14. P. Landini Molecular mechanisms of compounds affecting bacterial biofilm formation and dispersal Appl. Microbiol. Biotechnol. 86 2010 813 823
15. H. Esmail Understanding latent tuberculosis: the key to improved diagnostic and novel treatment strategies Drug Discov. Today 17 2012 514 521
16. B.B. Aldridge Asymmetry and aging of mycobacterial cells lead to variable growth and antibiotic susceptibility Science 335 2012 100 104
17. K. Pethe A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy Nat. Commun. 1 2010 57 10.1038/ncomms1060
18. Y. Hu A new approach for the discovery of antibiotics by targeting non-multiplying bacteria: a novel topical antibiotic for staphylococcal infections PLoS One 5 2010 E11818
19. P.A. Mak A high-throughput screen to identify inhibitors of ATP homeostasis in non-replicating Mycobacterium tuberculosis ACS Chem. Biol. 7 2012 1190 1197
20. M.O. Shleeva Dormant ovoid cells of Mycobacterium tuberculosis are formed in response to gradual external acidification Tuberculosis (Edinb.) 91 2011 146 154
21. A.H. Meijer, and H.P. Spaink Host-pathogen interactions made transparent with the zebrafish model Curr. Drug Targets 12 2011 1000 1017
22. E.J. Stoop Zebrafish embryo screen for mycobacterial genes involved in the initiation of granuloma formation reveals a newly identified ESX-1 component Dis. Model Mech. 4 2011 526 536
23. K. Takaki An in vivo platform for rapid high-throughput antitubercular drug discovery Cell Rep. 26 2012 175 184
24. G. Chamilos Drosophila melanogaster as a model host for the study of microbial pathogenicity and the discovery of novel antimicrobial compounds Curr. Pharm. Des. 17 2011 1246 1253
25. D. Bald, and A. Koul Respiratory ATP synthesis: the new generation of mycobacterial drug targets? FEMS Microbiol. Lett. 308 2010 1 7
26. A. Koul Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis J. Biol. Chem. 283 2008 25273 25280
27. S.P. Rao The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis Proc. Natl. Acad. Sci. U.S.A. 105 2008 11945 11950
28. M. Gengenbacher Nutrient-starved, non-replicating Mycobacterium tuberculosis requires respiration, ATP synthase and isocitrate lyase for maintenance of ATP homeostasis and viability Microbiology 156 2010 81 87
29. K. Andries A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis Science 307 2005 223 227
30. A.H. Diacon The diarylquinoline TMC207 for multidrug-resistant tuberculosis N. Engl. J. Med. 360 2009 2397 2405
31. A. Koul Diarylquinolines target subunit c of mycobacterial ATP synthase Nat. Chem. Biol. 3 2007 323 324
32. A.C. Haagsma Probing the interaction of the diarylquinoline TMC207 with its target mycobacterial ATP synthase PLoS One 6 2011 E23575
33. E.A. Weinstein Inhibitors of type II NADH:menaquinone oxidoreductase represent a class of antitubercular drugs Proc. Natl. Acad. Sci. U.S.A. 102 2005 4548 4553
34. T. Yano Reduction of clofazimine by mycobacterial type 2 NADH:quinone oxidoreductase: a pathway for the generation of bactericidal levels of reactive oxygen species J. Biol. Chem. 286 2011 10276 10287
35. D. van Soolingen The antipsychotic thioridazine shows promising therapeutic activity in a mouse model of multidrug-resistant tuberculosis PLoS One 5 2010 E12640
36. N. Veziris Sterilizing activity of second-line regimens containing TMC207 in a murine model of tuberculosis PLoS One 6 2011 E17556
37. K. Williams Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis Antimicrob. Agents Chemother. 56 2012 3114 3120
38. C. Vilhena, and A. Bettencourt Daptomycin: a review of properties, clinical use, drug delivery and resistance Mini Rev. Med. Chem. 12 2012 202 209
39. N. Ooi XF-70 and XF-73, novel antibacterial agents active against slow-growing and non-dividing cultures of Staphylococcus aureus including biofilms J. Antimicrob. Chemother. 65 2010 72 78
40. K.L. LaPlante, and L.A. Mermel In vitro activity of daptomycin and vancomycin lock solutions on staphylococcal biofilms in a central venous catheter model Nephrol. Dial. Transplant. 22 2007 2239 2246
41. A.C. Haagsma ATP synthase in slow- and fast-growing mycobacteria is active in ATP synthesis and blocked in ATP hydrolysis direction FEMS Microbiol. Lett. 313 2010 68 74
42. P. Lu Pyrazinoic acid decreases the proton motive force, respiratory ATP synthesis activity, and cellular ATP levels Antimicrob. Agents Chemother. 255 2011 5347 5354
43. A.C. Haagsma Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue Antimicrob. Agents Chemother. 53 2009 1290 1292
44. K.R. Allison Metabolite-enabled eradication of bacterial persisters by aminoglycosides Nature 473 2011 216 220
45. J.S. Kim Selective killing of bacterial persisters by a single chemical compound without affecting normal antibiotic-sensitive cells Antimicrob. Agents Chemother. 55 2011 5380 5383
46. N.M. Vega Signaling-mediated bacterial persister formation Nat. Chem. Biol. 8 2012 431 433
47. N. Dhar, and J.D. McKinney Mycobacterium tuberculosis persistence mutants identified by screening in isoniazid-treated mice Proc. Natl. Acad. Sci. U.S.A. 107 2010 12275 12280
48. B.D. Kana Depletion of resuscitation-promoting factors has limited impact on the drug susceptibility of Mycobacterium tuberculosis J. Antimicrob. Chemother. 65 2010 1583 1585
49. J. Wang Platensimycin is a selective FabF inhibitor with potent antibiotic properties Nature 441 2006 358 361
50. H.T. Wright, and K.A. Reynolds Antibacterial targets in fatty acid biosynthesis Curr. Opin. Microbiol. 10 2007 447 453
51. J. Wang, and H.O. Sintim Dialkylamino-2,4-dihydroxybenzoic acids as easily synthesized analogues of platensimycin and platencin with comparable antibacterial properties Chemistry 17 2011 3352 3357
52. S. Brinster Type II fatty acid synthesis is not a suitable antibiotic target for Gram-positive pathogens Nature 458 2009 83 86
53. Y. Yamamoto The Group B Streptococcus NADH oxidase Nox-2 is involved in fatty acid biosynthesis during aerobic growth and contributes to virulence Mol. Microbiol. 62 2006 772 785
54. W. Balemans Essentiality of FASII pathway for Staphylococcus aureus Nature 463 2010 E3
55. S.L. Tran, and G.M. Cook The F1Fo-ATP synthase of Mycobacterium smegmatis is essential for growth J. Bacteriol. 187 2005 5023 5028
56. Balemans, W. et al. Novel antibiotics with diarylquinoline chemical scaffold active on Gram-positive pathogenic bacteria. Antimicrob. Agents Chemother., in press
57. D.A. Mitchison Pyrazinamide-on the antituberculosis drug frontline Nat. Med. 2 1996 635 636
58. Y. Zhang, and D. Mitchison The curious characteristics of pyrazinamide: a review Int. J. Tuberc. Lung Dis. 7 2003 6 21
59. H. Sayahi Pyrazinamide, but not pyrazinoic acid, is a competitive inhibitor of NADPH binding to Mycobacterium tuberculosis fatty acid synthase I Bioorg. Med. Chem. Lett. 21 2011 4804 4807
60. W. Shi Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis Science 333 2011 1630 1632